Research and Markets: Brain Ischemia - Pipeline Review, H2 2015
28 November 2015 - 11:24AM
Business Wire
Research and Markets
(http://www.researchandmarkets.com/research/rj9bd8/brain_ischemia)
has announced the addition of the "Brain Ischemia - Pipeline
Review, H2 2015" report to their offering.
The report, Brain Ischemia - Pipeline Review, H2 2015, provides
an overview of the Brain Ischemia's therapeutic pipeline.
This report provides comprehensive information on the
therapeutic development for Brain Ischemia, complete with
comparative analysis at various stages, therapeutics assessment by
drug target, mechanism of action (MoA), route of administration
(RoA) and molecule type, along with latest updates, and featured
news and press releases.
It also reviews key players involved in the therapeutic
development for Brain Ischemia and special features on late-stage
and discontinued projects.
Key Topics Covered:
- Snapshot of the global therapeutic landscape of Brain
Ischemia
- Key pipeline products under drug profile section which includes
product description, MoA and R&D brief, licensing and
collaboration details & other developmental activities
- Key players involved in the therapeutics development for Brain
Ischemia and enlists all their major and minor projects
- All dormant and discontinued pipeline projects
- Brain Ischemia products under development by companies and
universities/research institutes based on information derived from
company and industry-specific sources
- Pipeline products coverage based on various stages of
development ranging from pre-registration till discovery and
undisclosed stages
- Detailed assessment of monotherapy and combination therapy
pipeline projects
- Coverage of the Brain Ischemia pipeline on the basis of target,
MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline
products
Benefits of this Report:
- Provides strategically significant competitor information,
analysis, and insights to formulate effective R&D development
strategies
- Identify emerging players with potentially strong product
portfolio and create effective counter-strategies to gain
competitive advantage
- Develop strategic initiatives by understanding the focus areas
of leading companies
- Identify and understand important and diverse types of
therapeutics under development for Brain Ischemia
- Plan mergers and acquisitions effectively by identifying key
players of the most promising pipeline
- Devise corrective measures for pipeline projects by
understanding Brain Ischemia pipeline depth and focus of Indication
therapeutics
- Develop and design in-licensing and out-licensing strategies by
identifying prospective partners with the most attractive projects
to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued
projects and understanding the factors that drove them from
pipeline
Companies Mentioned:
- CohBar Inc.
- Immune Pharmaceuticals Inc.
- Lixte Biotechnology Holdings, Inc.
- NeuroNascent, Inc.
- NeurOp, Inc
- Prolong Pharmaceuticals
- Spectrum Pharmaceuticals, Inc.
- Sylentis S.A.
- The International Biotechnology Center (IBC) Generium
- Vect-Horus S.A.S
For more information visit
http://www.researchandmarkets.com/research/rj9bd8/brain_ischemia
View source
version on businesswire.com: http://www.businesswire.com/news/home/20151127005400/en/
Research and MarketsLaura Wood, Senior
Managerpress@researchandmarkets.comFor E.S.T Office Hours Call
1-917-300-0470For U.S./CAN Toll Free Call 1-800-526-8630For GMT
Office Hours Call +353-1-416-8900U.S. Fax: 646-607-1907Fax (outside
U.S.): +353-1-481-1716Sector: Central Nervous System